| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/ANNONC/MDN058 |
| P8608 | Fatcat ID | release_6oqx6iu46fbonez6cnt4x7nqcu |
| P698 | PubMed publication ID | 18349029 |
| P5875 | ResearchGate publication ID | 5503503 |
| P2093 | author name string | A Roth | |
| A Trojan | |||
| A Kappeler | |||
| B Pestalozzi | |||
| D Dietrich | |||
| D Koeberle | |||
| T Ruhstaller | |||
| V Hess | |||
| M Borner | |||
| D Rauch | |||
| W Mingrone | |||
| C Caspar | |||
| P Saletti | |||
| D Helbling | |||
| Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland | |||
| D Lanz | |||
| R Von Moos | |||
| P2860 | cites work | Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 |
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer | Q33978749 | ||
| Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 | ||
| Epidermal growth factor receptor targeting in cancer | Q36557269 | ||
| Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer | Q43871119 | ||
| Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer | Q43937160 | ||
| Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial | Q44313163 | ||
| Small proportions: what to report for confidence intervals? | Q44339739 | ||
| Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer | Q46892017 | ||
| KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab | Q46903224 | ||
| P433 | issue | 7 | |
| P921 | main subject | colorectal cancer | Q188874 |
| capecitabine | Q420207 | ||
| cetuximab | Q420296 | ||
| oxaliplatin | Q422327 | ||
| colorectal carcinoma | Q25493920 | ||
| phase II clinical trial | Q42824440 | ||
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 1288-1292 | |
| P577 | publication date | 2008-03-17 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. | |
| P478 | volume | 19 |
| Q33445357 | A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer |
| Q34580450 | A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial |
| Q33922925 | Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial |
| Q37856053 | Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab |
| Q37593624 | Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. |
| Q21198850 | Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review |
| Q52657104 | Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis. |
| Q26827240 | Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier? |
| Q57424151 | Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer |
| Q37316037 | Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer |
| Q38644154 | Combination Adjuvant Chemotherapy with Targeted Drugs for Treatment of Colorectal Cancer: A Network Meta-Analysis. |
| Q35125643 | Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial |
| Q33759532 | Current status of pharmacological treatment of colorectal cancer |
| Q38133409 | Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management |
| Q47369045 | Does the Addition of Biologic Agents to Chemotherapy in Patients with Unresectable Colorectal Cancer Metastases Result in a Higher Proportion of Patients Undergoing Resection? A Systematic Review and Meta-analysis |
| Q35746635 | Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature |
| Q38207148 | Does the addition of targeted biological agents to first-line chemotherapy for advanced colorectal cancer increase complete response? A systematic review and meta-analysis |
| Q26777704 | Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis |
| Q53159209 | Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials. |
| Q38666172 | Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. |
| Q40014365 | Evolving role of cetuximab in the treatment of colorectal cancer |
| Q52666988 | FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis. |
| Q36368646 | Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial |
| Q37771245 | First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab |
| Q43276118 | Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? |
| Q43241630 | Implications of KRAS mutation status for the treatment of metastatic colorectal cancer |
| Q34537664 | Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis |
| Q36649908 | Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis |
| Q36100844 | KRAS mutant colorectal tumors: past and present |
| Q24598640 | Markers of resistance to anti-EGFR therapy in colorectal cancer |
| Q30249335 | Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. |
| Q37642801 | Metastatic colorectal cancer: recent advances in its clinical management |
| Q37376993 | Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines |
| Q35001415 | Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab |
| Q26828735 | Molecularly targeted drugs for metastatic colorectal cancer |
| Q35807573 | Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. |
| Q34621577 | New trends in epidermal growth factor receptor-directed monoclonal antibodies |
| Q83978403 | Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis |
| Q37242664 | Oxaliplatin-based chemotherapy in the management of colorectal cancer |
| Q36611365 | PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients |
| Q36977022 | Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial |
| Q34488787 | Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342 |
| Q64124469 | Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping |
| Q48254405 | Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential |
| Q34761646 | Rash rates with egfr inhibitors: meta-analysis |
| Q37706186 | Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature |
| Q54288828 | Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials. |
| Q48226075 | Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial. |
| Q38103465 | Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. |
| Q37230238 | Role of oxaliplatin in the treatment of colorectal cancer |
| Q41947800 | Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer |
| Q28088693 | Standard chemotherapy with cetuximab for treatment of colorectal cancer |
| Q37269197 | Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab |
| Q38917649 | The Pharmacological Costs of Complete Liver Resections in Unselected Advanced Colorectal Cancer Patients: Focus on Targeted Agents. A Review of Randomized Clinical Trials |
| Q64230605 | The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer |
| Q35583683 | The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development |
| Q38268544 | The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients: a review of published Phase II and III trials |
| Q35989994 | The risk for anemia with targeted therapies for solid tumors |
| Q36498461 | The role of cetuximab as first-line treatment of colorectal liver metastases |
| Q37130603 | The role of personalized medicine in metastatic colorectal cancer: an evolving landscape |
| Q82824248 | The treatment of co-morbidities in older patients with metastatic cancer |
| Q37081059 | Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience |
| Q26747335 | Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer |
| Q37225720 | Treatment in advanced colorectal cancer: what, when and how? |
| Q34088424 | Understanding resistance to EGFR inhibitors-impact on future treatment strategies |
| Q37839084 | XELOX in colorectal cancer: a convenient option for the future? |
Search more.